Almirall, S.A. (ALM.MC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Carlos Gallardo Piqué | CEO, President, Member of Management Board & Chairman of the Board | 50k | -- | 1972 |
| Mr. Eloi Crespo Cervera | Chief Industrial Operations Officer & Member of Management Board | -- | -- | -- |
| Mr. Esteve Conesa Panicot | Chief People & Culture Officer and Member of Management Board | -- | -- | -- |
| Dr. Volker Koscielny | Chief Medical Officer & Member of Management Board | -- | -- | -- |
| Dr. Karl Ziegelbauer | Chief Scientific Officer & Member of Management Board | -- | -- | -- |
| Mr. Paolo Cionini | Chief Commercial Officer Europe & International and Member of Management Board | -- | -- | -- |
| Ms. Isabel Cristina Gomes | Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board | -- | -- | -- |
| Ms. Mercedes Diz Lopez | Chief Marketing Officer & Member of Management Board | -- | -- | -- |
| Mr. Pablo Divasson del Fraile | Senior Director of Investor Relations | -- | -- | -- |
| Xavier Llaurado Alba | Acting CSO and Head of R&D | -- | -- | -- |
Almirall, S.A.
- Sector:?
- Healthcare
- Industry:? Drug Manufacturers - Specialty & Generic
- Full Time Employees:?
- 1,996
Description
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Corporate Governance
Upcoming Events
November 11, 2024 at 6:28 AM UTC
Almirall, S.A. Earnings Date
Recent Events
May 17, 2024 at 12:00 AM UTC
Ex-Dividend Date